An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate...

Area of Science:

• Pharmacogenomics
• Human Immunodeficiency Virus (HIV) Research
• Clinical Chemistry

Background:

• Nucleoside reverse transcriptase inhibitors, tenofovir alafenamide fumarate and tenofovir disoproxil fumarate, are standard HIV treatments.
• Laboratory monitoring is essential for assessing tenofovir efficacy and patient tolerability.
• Investigating genetic factors may optimize tenofovir-based therapies.

Purpose of the Study:

• To explore the relationship between single nucleotide polymorphisms (SNPs) and clinical parameters in patients receiving tenofovir.
• To identify potential genetic markers influencing tenofovir treatment outcomes.
• To lay the groundwork for personalized medicine approaches in HIV management.

Main Methods:

• Genetic variations were analyzed in a study population using the iPLEX ADME PGx Pro v1.0 Panel.
• The study cohort comprised predominantly Caucasian males with a median age of 53.0 years.
• Analysis focused on identifying associations between specific SNPs and clinical data.

Main Results:

• Several single nucleotide polymorphism (SNP) relationships were identified with both tenofovir prodrugs.
• Observed SNP associations were often within comprehensive regimen groupings.
• Distinguishing the effects of tenofovir alafenamide fumarate versus tenofovir disoproxil fumarate based on SNPs proved challenging.

Conclusions:

• This exploratory study identified potential genetic associations warranting further investigation.
• Findings suggest that pharmacogenomic analysis could refine tenofovir treatment strategies.
• Further research is needed to validate SNP associations and their clinical utility in HIV care.